Armata Pharmaceuticals, Inc. (ARMP) Fair Value 2026

ARMP · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.1 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (17/100)

Quick Summary — As of 2026-08-28, Armata Pharmaceuticals, Inc. (ARMP) trades at $5.37. QOC: 4.1/10. Value Trap Risk: 17/100 (SAFE). 1/13 models active.

Key Facts

Ticker
ARMP
Price
$5.37
Quality Score
4.1/10
Value Trap Risk
17/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.1/10 signals weak fundamentals

What Fair Value Does Each Model Give ARMP?

1 Intrinsic Value Models vs. Current Price ($5.37)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $1.21 -77.4%

All Models Active

All 1 models are displayed above.

What Is Armata Pharmaceuticals, Inc. (ARMP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Armata Pharmaceuticals, Inc.'s intrinsic value is estimated at $1.21. Trading at its current price of $5.37, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -77.4%.

What Do the Models Say About ARMP?

1 of 13 models are currently active for ARMP. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does ARMP Rank in Biotechnology?

Among 625 Biotechnology stocks, ARMP ranks #517 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Armata Pharmaceuticals, Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including partnership and licensing deals — shape both the opportunity set and risk profile.

Is ARMP a Value Trap?

CirclFi's Value Trap algorithm assigns ARMP a score of 17/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Armata Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Armata Pharmaceuticals, Inc. earns a quality score of 4.1/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ARMP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ARMP's 1 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Armata Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

AKTXAkari Therapeutics, PlcQOC 4.1GTBPGT Biopharma, Inc.QOC 4.1CNTNCanton Strategic Holdings, Inc.QOC 4.2TVRDTvardi Therapeutics, Inc.QOC 4.1RNTXRein Therapeutics Inc.QOC 4.2MTNBMatinas BioPharma Holdings, Inc.QOC 4.1ANABAnaptysBio, Inc.QOC 7.0KYNBKyntra Bio, Inc.QOC 5.6REPLReplimune Group, Inc.QOC 4.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: AKTX · GTBP · CNTN · TVRD · RNTX · MTNB · ANAB · KYNB · REPL · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ARMP?

6 companies across all industries closest to ARMP’s Quality of Company score of 4.1/10.

BIOFBlue Biofuels, Inc.QOC 4.1GRPSGold River Productions, Inc.QOC 4.1IMOImperial Oil LimitedQOC 4.1DBMMDigital Brand Media & Marketing Group, Inc.QOC 4.1RAINRain Enhancement Technologies Holdco, Inc.QOC 4.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BIOF · GRPS · IMO · DBMM · RAIN · NVDA

Where Does ARMP Sit in CirclFi's Biotechnology Rankings?

ARMP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Armata Pharmaceuticals, Inc.’s Valuation?

What is Armata Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Armata Pharmaceuticals, Inc. (ARMP). The Quality of Company score is 4.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ARMP overvalued or undervalued right now?

At $5.37, 0 of 1 active models suggest ARMP may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Armata Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.1 mean for ARMP?

Armata Pharmaceuticals, Inc.'s QOC of 4.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ARMP?

CirclFi analyzes ARMP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is ARMP a value trap in 2026?

Armata Pharmaceuticals, Inc.'s Value Trap score is 17/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Armata Pharmaceuticals, Inc. (ARMP) a Quality of Company score of 4.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ARMP/ · Methodology
Primary sources for this ARMP valuation
  • Financial statements: Armata Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000921114) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ARMP as of ; valuations recomputed .